AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17806025
Drug: Post‐incisional wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post‐incisional wound infiltration with levobupivacaine 1.25 mg/kg
Trial: 17806025
Drug: Paracetamol 30
RxNorm normalized name: Paracetamol 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 30 mg/kg administered rectally
Trial: 11094004
Drug: Ketamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (25 mg/24 h)
Trial: 27660289
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein treatment
Trial: 27660289
Drug: Zinc, selenium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc, selenium, glutamine, and metoclopramide treatment
Trial: 19135567
Drug: 20 mcg
RxNorm normalized name: Caverject 20 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg of EE and 150 mcg of desogestrel (DSG) for 6 months
Trial: 19135567
Drug: 30 mcg
RxNorm normalized name: Avonex 30 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mcg of EE and 2 mg of chlormadinone acetate (CMA) for 6 months
Trial: 19135567
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (EE/DSG and EE/CMA)
Trial: 17386385
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of technetium 99m sestamibi at 30 to 60 minutes after balloon inflation (group 1, n = 20)
Trial: 17386385
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of technetium 99m sestamibi at 90 to 120 minutes after balloon inflation (group 2, n = 10)
Trial: 8989332
Drug: Ceftriaxone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (single intramuscular dose, maximum dose of 50 mg/kg)
Trial: 8989332
Drug: Trimethoprim-sulfamethoxazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (10 days of oral treatment, 8 mg of TMP and 40 mg of SMZ/kg/day in two divided doses)
Trial: 23849005
Drug: Community pharmacist's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacist's intervention (drug dosing adjustment service)
Trial: 16670361
Drug: 5‐HT3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT3 receptor antagonist (5‐HT3RA) plus dexamethasone
Trial: 16670361
Drug: 5‐HT3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT3 receptor antagonist (5‐HT3RA)
Trial: 12005142
Drug: Astra Tech
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Astra Tech implants
Trial: 10437252
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) drugs for supporting healthy energy and removing blood stasis
Trial: 3061846
Drug: Lymecycline therapy
RxNorm normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline therapy (300 mg b.i.d. for 14 days)
Trial: 3061846
Drug: Lymecycline therapy
RxNorm normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline therapy
Trial: 3061846
Drug: Lymecycline therapy
RxNorm normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline therapy and Placebo
Trial: 16526560
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg TLP (Talampanel) administered orally in fasted and fed states.
Trial: 12517808
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg/m2)
Trial: 12517808
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg/m2)
Trial: 10644869
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccination after one dose of GM-CSF (24 hours post-administration)
Trial: 10644869
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of hepatitis B vaccine after one dose of GM-CSF (24 hours post-administration)
Trial: 10644869
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of hepatitis B vaccine alone (control for booster dose)
Trial: 2252161
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (IT) with an alginate-conjugated extract of D. pteronyssinus
Trial: 6794308
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin daily for 6 weeks
Trial: 28401794
Drug: Low-dose radioiodine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radioiodine (1850 MBq)
Trial: 28401794
Drug: High-dose radioiodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radioiodine (3700 MBq)
Trial: 24360978
Drug: High-dose soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose soy isoflavone (300 mg/day)
Trial: 9573762
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg daily for 5 days a week)
Trial: 29464504
Drug: 2 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/h of propofol (P2)
Trial: 29464504
Drug: 1 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/h of propofol (P1)
Trial: 29464504
Drug: 0.5 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg/h of propofol (P0.5)
Trial: 24424711
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg rimonabant
Trial: 22754096
Drug: succinylcholine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine (1.0 mg/kg BW)
Trial: 22754096
Drug: rocuronium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium (0.5 mg/kg BW)
Trial: 22754096
Drug: saline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline (15 mL)
Trial: 19924124
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (300 mg t.i.d.)
Trial: 19924124
Drug: Ritonavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (300 mg b.i.d.)
Trial: 18515308
Drug: Daily orally
RxNorm normalized name: Daily Hist Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily orally administered calcitriol
Trial: 18515308
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and intravenous calcitriol)
Trial: 8843129
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (first half of therapy)
Trial: 8843129
Drug: Antioxidant supplements
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplements (second half of therapy)
Trial: 1609035
Drug: Buprenorphine (1.5-8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (1.5-8.0 mg/day)
Trial: 1609035
Drug: Dose reductions
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reductions (10% twice weekly for 5 weeks to zero dose, then placebo for 2 weeks)
Trial: 1609035
Drug: Stable dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable dose for 7 weeks
Trial: 1609035
Drug: Discontinuation trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation trial (n = 51)
Trial: 3086061
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg enteric-coated granules, once daily for nine days
Trial: 30220235
Drug: Nintedanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib plus Sildenafil (nintedanib at a dose of 150 mg twice daily plus sildenafil at a dose of 20 mg three times daily)
Trial: 30220235
Drug: Nintedanib (nintedanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (nintedanib at a dose of 150 mg twice daily plus placebo three times daily)
Trial: 19126851
Drug: Concurrent tracking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent tracking task during stepping trials
Trial: 19126851
Drug: No concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No concurrent tracking task during stepping trials
Trial: 12967799
Drug: Ahmed glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed glaucoma valve implant
Trial: 10898322
Drug: Famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 500 mg three times daily (tid)
Trial: 10898322
Drug: Famciclovir 125
RxNorm normalized name: famciclovir 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 125 mg, 250 mg, 500 mg three times daily (tid)
Trial: 9273203
Drug: 1% histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% histamine solution
Trial: 31433304
Drug: DOR 100
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DOR 100 mg + TDF 300 mg (Study 1)
Trial: 31433304
Drug: DOR 100
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DOR 100 mg + 3TC 300 mg + TDF 300 mg (Study 2)
Trial: 31433304
Drug: 3TC 300
RxNorm normalized name: 3TC 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3TC 300 mg + TDF 300 mg (Study 2)
Trial: 24594678
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of LSD
Trial: 24594678
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg of LSD (with crossover to 200 μg after unmasking)
Trial: 19562652
Drug: Cranberry (C)
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry (C) two times daily (C, C; n = 10 pregnant)
Trial: 19562652
Drug: Placebo two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two times daily (P, P; n = 8 pregnant)
Trial: 19102746
Drug: Artemether-lumefantrine tablets
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine tablets (Coartem)
Trial: 19102746
Drug: Artemether-lumefantrine suspension
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine suspension (Co-artesiane)
Trial: 15480571
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate (2 g daily)
Trial: 7598056
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g alcohol/d for three menstrual cycles
Trial: 2115613
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose (HD) of 0.1 mg/sqm, three times a week
Trial: 2115613
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose (LD) of 0.01 mg/sqm, three times a week
Trial: 2115613
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant gamma‐interferon (r‐IFN‐gamma) therapy
Trial: 31060615
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg elemental iron and 2.8 mg folic acid
Trial: 28586713
Drug: Guided Internet-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-Based Cognitive Behavior Therapy (ICBT) for 8 weeks
Trial: 26125951
Drug: Tier 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tier 2 narrative language intervention, small-group (4:1), 15-20 min, twice a week, for 9 weeks
Trial: 1312770
Drug: Intra-arterial therapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial therapy
Trial: 24174612
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement treatment plus brief physician advice and 8 weeks of nicotine replacement therapy (NRT)
Trial: 20593912
Drug: Budesonide/formoterol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol fixed maintenance dose (640 microg/18 microg per day)
Trial: 20593912
Drug: Budesonide/formoterol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol maintenance and reliever therapy (320 microg/9 microg per day plus additional inhalations as needed)
Trial: 20593912
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate fixed maintenance dose (100 microg/500 microg per day plus terbutaline as needed)
Trial: 10098429
Drug: Adjuvant postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant postoperative radiotherapy (conventional roentgen, electron beams, and high‐energy photon beams) with a target dose of 38‐48 Gy, administered in daily fractions of 1.9‐2.4 Gy, 5 days/week.
Trial: 1974513
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of 50 mg carvedilol
Trial: 31254190
Drug: Monthly ring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly ring
Trial: 28759403
Drug: Metformin 1
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1 g/d for 6 months
Trial: 23771713
Drug: Conservative drug
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative drug therapy
Trial: 12652148
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin infusion with bedside aPTT testing and computerized algorithmic adjustment
Trial: 7742156
Drug: New microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New microemulsion oral formulation (NEO)
Trial: 7742156
Drug: Soft gelatine
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatine capsule (SGC)
Trial: 28319494
Drug: Heparin derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin derivatives
Trial: 26552068
Drug: 1.2% atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% atorvastatin
Trial: 24640583
Drug: RLX (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLX (40 mcg/d) plus rehabilitation
Trial: 21878434
Drug: Darexaban 10
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darexaban 10 mg o.d.
Trial: 21878434
Drug: Darexaban 30
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darexaban 30 mg b.i.d.
Trial: 21878434
Drug: Darexaban 60
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darexaban 60 mg o.d.
Trial: 17492272
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous citalopram
Trial: 15364775
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody recognizing IL-8 (800-mg loading dose; 400-mg subsequent doses)
Trial: 15364775
Drug: Placebo (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (active buffer solution)
Trial: 11277373
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily chest radiographs
Trial: 9766831
Drug: Oral appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral appliances for the management of chronic myalgia of the jaw muscles
Trial: 2596599
Drug: Prednisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (20 mg three times daily for 5 days)
Trial: 4119162
Drug: Ragweed extract
RxNorm normalized name: Ragweed pollen extract
DrugBank: Ragweed pollen extract (DB05368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed extract immunotherapy
Trial: 23290075
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine (Shaofu Zhuyu formula concentrated-granule, SFZYFG) therapy
Trial: 18442638
Drug: Metformin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (0.5 g 3 times a day)
Trial: 15890685
Drug: AMD3100 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMD3100 plus G-CSF (A + G)
Trial: 15890685
Drug: G-CSF alone
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF alone (G)
Trial: 11641591
Drug: Fluindione plus
RxNorm normalized name: fluindione
DrugBank: Fluindione (DB13136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluindione plus aspirin (100 mg)
Trial: 11641591
Drug: Fluindione plus
RxNorm normalized name: fluindione
DrugBank: Fluindione (DB13136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluindione plus placebo (anticoagulant alone)
Trial: 9617462
Drug: r‐hEPO (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐hEPO (all doses)
Trial: 27625301
Drug: MK‐7 375 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐7 375 µg for 12 months
Trial: 19962839
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care provided at month 2
Trial: 15751670
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 200 mg added to 500 mL NaCl and perfused for 180 min after induction of anaesthesia and 100 mg PTX added to warm cardioplegic solution
Trial: 15751670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline solution as placebo)
Trial: 2493732
Drug: Continuous nitroglycerin
RxNorm normalized name: nitroglycerin Extended Release Oral Tablet [Nitrocontin Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nitroglycerin therapy (active drug patches worn for 24 hours)
Trial: 2493732
Drug: Intermittent nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nitroglycerin therapy (12-hour active drug followed by 12-hour nitrate-free period)
Trial: 25741640
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered with SoloSTAR® or ClikSTAR® pens
Trial: 17185119
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and Ibuprofen
Trial: 15379308
Drug: Periocline (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocline (2% minocycline hydrochloride ointment)
Trial: 9771304
Drug: Tropisetron 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 0.1 mg kg‐1
Trial: 18332472
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg/d orally)
Trial: 16567978
Drug: MMR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR and varicella vaccine followed by Hib/HepB and DTaP 42 days later
Trial: 14562776
Drug: Totally intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Totally intravenous anaesthesia (propofol and remifentanil)
Trial: 10801250
Drug: Lactate capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate capsule (control)
Trial: 3912190
Drug: Baclofen 10
RxNorm normalized name: baclofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 10 mg orally
Trial: 31314965
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (combination prevention intervention with universal antiretroviral therapy [ART])
Trial: 24724863
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusions at counts of fewer than 10 × 10(9) /L
Trial: 22607479
Drug: Budesonide/formoterol (Symbicort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (Symbicort Turbuhaler SMART™), starting dose 160 mg/4.5 mg two inhalations twice daily plus as-needed inhalations
Trial: 22607479
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (Seretide Diskus), starting dose 50 mg/250 mg bid plus salbutamol as needed
Trial: 20819525
Drug: Somatostatin administration
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin administration (group B)
Trial: 15763644
Drug: tamoxifen monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamoxifen monotherapy